Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 394

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 394
---
-term loans and advances and other non-current receivables(a)            |   502 |   591 |   452 |
| Derivative financial instruments (Note D.20.)                                |     — |     — |     — |
| Total                                                                        | 3,753 | 3,218 | 3,095 |

(a) As of December 31, 2024 , this line includes:

– Loan of € 149 million to the BioAtrium joint venture which matures on December 1, 2031, of which € 156million was recognized in "Other current

assets" as of December 31, 2022;

– a receivable under a sub-lease amounting to € 116 million ( € 181 million before discounting), versus € 132 million (or € 195 million before discounting) as

of December 31, 2023 .

D.7.1. Equity instruments at fair value through other comprehensive income

Quoted equity instruments

The line “Equity instruments at fair value through other comprehensive income” includes equity investments quoted in an active

market with a carrying amount of € 467million as of December 31, 2024 , € 470million as of December 31, 2023 and € 387million

as of December 31, 2022 .

The movement i n quoted equity investments included in the “Equity instruments at fair value through other comprehensive

income” category in the year ended December 31, 2024 was mainly due to Sanofi taking a non-controlling equity interest in

Novavax in May 2024.

The main changes during previous years in quoted equity investments included in the “Equity instruments at fair value through

other comprehensive income” category are described below:

• In 2023 : t here were no material movements in quoted equity investments during the year ended December 31, 2023.

• In 2022 :

– the sale in June 2022 of the residual equity interest in Regeneron (see Note C.1.) for $ 174million , the entire loss on which

was recorded within Other comprehensive income , and

– the acquisition of an equity interest in Innovent Biologics, in connection with a strategic collaboration agreement to

intensify development in oncology medicines signed in August 2022, which had a fair value of € 250million as of that date

and € 228million as of December 31,